Article and Video CATEGORIES
The report of the phase II randomized trial of MEK inhibitor selumetinib for KRAS mutation-positive NSCLC was just published in Lancet Oncology. Here's my discussion of some of the highlights of this work and what this means.
[powerpress]
I'm hoping we'll have more information to update everyone on the developments in the story of MEK inhibitors for KRAS mutation-positive NSCLC, and perhaps also a broader population of patients with NSCLC, in the next year or two.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Radiation + Brain Operation has just been discarded due to high risk. They will double Tagrisso dosis and then wait to see if it works, then try traditional Chemo. I would...
Hi and welcome to GRACE. I'm sorry to know you are entering a new stage. I'm not about to comment just now but wanted to let you know I see your...
Edit to say, we can't give advice but we can comment with views and facts. :)
My first thought is to ask if she has been seen at a large...
Hi Barbro, Welcome to GRACE. I'm sorry you're worrying about this. We aren't able to give feedback on scan reports. Interpreting scan reports in this setting is not only unethical but...
Thank you, Janine, for answering so rapidly. I am aware that my nodules are small, but they scare me all the same. Your words that nodule measurements may vary somewhat when...
Hi Barbro, I'm sorry you're worrying about this, and don't feel like you can discuss this with your doctor. Speak to your doctor about this. Let them know your worries and...
Hi Bluebird, Welcome to GRACE. I'm sorry you're going through this scare and hope it's just inflammation or from an infection you didn't know you had.
A CT would be...